TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04427215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
Study: NCT02385318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Perrigo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT04427215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
Study: NCT01780662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study: NCT00423605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: flexible dosing
Study: NCT00396292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron tablets
Description: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-45
Description: A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
Study: NCT01780662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT00085735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01233973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video
Study: NCT02419560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 and Ibrutinib Combination
Description: Both are administered orally once daily.
Study: NCT01278368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic resection after preoperative chemotherapy
Description: Pancreatic resection after preoperative chemotherapy
Study: NCT00199563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viagra
Description: Sildenafil 100mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra
Description: Sildenafil 100mg daily for 12 weeks
Study: NCT01278368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic resection
Description: Pancreatic resection
Study: NCT01204242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Study: NCT02092194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Dose Online HDF
Description: Convection volume; 33-43 L/treatment (140-180 mL/min)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Online HDF
Description: convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
Study: NCT03166033

Intervention type: OTHER
Intervention: the disease
Description: Observation the patients and non-patients

Intervention type: OTHER
Intervention: the disease
Description: Observation the patients and non-patients
Study: NCT00881400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
Study: NCT03072056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study: NCT01204242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Study: NCT04319224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05165784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using V technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using V technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using palpation technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral vein identification
Description: Femoral vein identification using palpation technique
Study: NCT02834273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke education workshops
Study: NCT02905708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Activated heating packs
Description: The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming Device
Description: forced air-warming inflatable device applied according to standard hospital protocol.
Study: NCT02631057

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin tablet (adjustment by each patients)
Study: NCT00732914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib (Sutent)
Description: Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Description: Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
Study: NCT04336683

Intervention type: DEVICE
Group type: OTHER
Intervention: Interstitial and intracavitary brachytherapy
Description: Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
Study: NCT04639882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Description: Information presenting perceived and actual drinking norms.
Study: NCT02475148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446
Study: NCT03072056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study: NCT02475148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446
Study: NCT02264990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Oral capsule, administered twice daily for 7 days in each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by Intravenous infusion on Day 1 of each 21-day cycle
Study: NCT03473496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART therapy in Relapsed/Refractory multiple myeloma
Description: one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
Study: NCT04368156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore® (Vagus nerve stimulation)
Description: Vagus nerve stimulation using the gammacore neurostimulation device
Study: NCT01639677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Description: Laparoscopic gastric bypass surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic VBG
Description: Laparoscopic vertical banded gastroplasty
Study: NCT03445455

Intervention type: DEVICE
Intervention: Tidal volume measurement
Description: Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask.
Study: NCT04345744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic and 0.2% chlorhexidine mouth rinse
Description: The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% mouth rinse
Description: The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
Study: NCT02057783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will carry out 3 times per week during 12 weeks for intervention arm
Study: NCT01859442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structured responsive interval exercise training programme

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: NO intervention in this group, only standard care (no exercise programme)
Study: NCT01195129

Intervention type: DEVICE
Group type: OTHER
Intervention: MicroVention Hydrogel coil
Description: Micro Vention Hydrogel Coils

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-hydrogel coils
Description: Cerecyte or bare platinum coils
Study: NCT01452334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti PD-L1)
Description: Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
Study: NCT04381910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610( Irinotecan hydrochloride liposome injection )
Description: LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
Study: NCT02972255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: RO7079901 will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: RO7079901 will be administered as per schedule described in individual arm.
Study: NCT01501916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: daily dosage of 50 µg Vitamin D3 for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of placebo
Study: NCT02972255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: RO7079901 will be administered as per schedule described in individual arm.
Study: NCT02475148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02972255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO7049389 Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO7049389 Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO7049389 Placebo
Description: Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Placebo
Description: Placebo matching to meropenem will be administered as per schedule described in individual arm.
Study: NCT01595152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate
Description: 8 mg once daily for 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine
Description: 8 mg, once daily for 60 dyas
Study: NCT06180954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LOXO-305
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LOXO-305
Description: Administered IV
Study: NCT03098329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ct/GC screening
Description: Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
Study: NCT03824808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
Description: Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
Study: NCT00586495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
Study: NCT03469765

Intervention type: OTHER
Intervention: does not apply
Description: biological sample taking: urine, blood
Study: NCT03173092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone.
Study: NCT04019730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)
Study: NCT00087009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT03849378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sargassum Horneri Extract group
Description: This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
Study: NCT04361591

Intervention type: OTHER
Intervention: Observational only
Description: Observational Study
Study: NCT04149067

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Evaluation of the effectiveness and safety of the Dapagliflozin treatment.

Intervention type: DRUG
Intervention: Sitagliptin
Description: Evaluation of the effectiveness and safety of the Sitagliptin treatment.
Study: NCT01495221

Intervention type: DRUG
Group type: OTHER
Intervention: Alfilbercept
Description: All patients will receive 2.0 mg intravitreal aflibercept injection.
Study: NCT03157024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring Sham (RS)
Study: NCT01029366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.